Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer’s Disease: A Systematic Review and Meta-analysis of Preclinical Studies
Restricted accessReview articleFirst published online April 30, 2024
Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer’s Disease: A Systematic Review and Meta-analysis of Preclinical Studies
Alzheimer’s disease (AD), the most common form of dementia, remains long-term and challenging to diagnose. Furthermore, there is currently no medication to completely cure AD patients. Rapamycin has been clinically demonstrated to postpone the aging process in mice and improve learning and memory abilities in animal models of AD. Therefore, rapamycin has the potential to be significant in the discovery and development of drugs for AD patients.
Objective:
The main objective of this systematic review and meta-analysis was to investigate the effects and mechanisms of rapamycin on animal models of AD by examining behavioral indicators and pathological features.
Methods:
Six databases were searched and 4,277 articles were retrieved. In conclusion, 13 studies were included according to predefined criteria. Three authors independently judged the selected literature and methodological quality. Use of subgroup analyses to explore potential mechanistic effects of rapamycin interventions: animal models of AD, specific types of transgenic animal models, dosage, and periodicity of administration.
Results:
The results of Morris Water Maze (MWM) behavioral test showed that escape latency was shortened by 15.60 seconds with rapamycin therapy, indicating that learning ability was enhanced in AD mice; and the number of traversed platforms was increased by 1.53 times, indicating that the improved memory ability significantly corrected the memory deficits.
CONCLUSIONS:
Rapamycin therapy reduced age-related plaque deposition by decreasing AβPP production and down-regulating β-secretase and γ-secretase activities, furthermore increased amyloid-β clearance by promoting autophagy, as well as reduced tau hyperphosphorylation by up-regulating insulin-degrading enzyme levels.
FerriCP, PrinceM, BrayneC, BrodatyH, FratiglioniL, GanguliM, HallK, HasegawaK, HendrieH, HuangY, JormA, MathersC, MenezesPR, RimmerE, ScazufcaM (2005) Global prevalence of dementia: A Delphi consensus study. . Lancet366, 2112–2117.
3.
BrandL, NicholsK, WangH, ShenL, HuangH (2020) Joint multi-modal longitudinal regression and classification for Alzheimer’s disease prediction. . IEEE Trans Med Imaging39, 1845–1855.
4.
SunX, MengX, ZhangJ, LiY, WangL, QinX, SuiN, ZhangY (2012) GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment. . J Alzheimers Dis31, 635–649.
5.
HerrmannN, ChauSA, KircanskiI, LanctôtKL (2011) Current and emerging drug treatment options for Alzheimer’s disease: A systematic review. . Drugs71, 2031–2065.
6.
ShiM, ChuF, ZhuF, ZhuJ (2022) Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: A focus on aducanumab and lecanemab. . Front Aging Neurosci14, 870517.
7.
MeikleL, PollizziK, EgnorA, KramvisI, LaneH, SahinM, KwiatkowskiDJ (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. . J Neurosci28, 5422–5432.
HalloranJ, HussongSA, BurbankR, PodlutskayaN, FischerKE, SloaneLB, AustadSN, StrongR, RichardsonA, HartMJ, GalvanV (2012) Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. . Neurosci223, 102–113.
SimanR, CoccaR, DongY (2015) The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS One10, e0142340.
13.
McGowanE, PickfordF, KimJ, OnsteadL, EriksenJ, YuC, SkipperL, MurphyMP, BeardJ, DasP, JansenK, DeLuciaM, LinWL, DoliosG, WangR, EckmanCB, DicksonDW, HuttonM, HardyJ, GoldeT (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. . Neuron47, 191–199.
14.
CaccamoA, MajumderS, RichardsonA, StrongR, OddoS (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. . J Biol Chem285, 13107–13120.
15.
MajumderS, RichardsonA, StrongR, OddoS (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One6, e25416.
16.
LinAL, ZhengW, HalloranJJ, BurbankRR, HussongSA, HartMJ, JavorsM, ShihYY, MuirE, Solano FonsecaR, StrongR, RichardsonAG, LechleiterJD, FoxPT, GalvanV (2013) Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer’s disease. . J Cereb Blood Flow Metab33, 1412–1421.
17.
PierceA, PodlutskayaN, HalloranJJ, HussongSA, LinPY, BurbankR, HartMJ, GalvanV (2013) Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer’s-like deficits in mice modeling the disease. . J Neurochem124, 880–893.
18.
SpilmanP, PodlutskayaN, HartMJ, DebnathJ, GorostizaO, BredesenD, RichardsonA, StrongR, GalvanV (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of alzheimer’s disease. PLoS One5, e9979.
19.
CaccamoA, DePinto V, MessinaA, BrancaC, OddoS (2014) Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. . J Neurosci34, 7988–7998.
20.
LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GøtzschePC, IoannidisJP, ClarkeM, DevereauxPJ, KleijnenJ, MoherD (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ339, b2700.
HooijmansCR, RoversMM, deVries RB, LeenaarsM, Ritskes-HoitingaM, LangendamMW (2014) SYRCLE’s risk of bias tool for animal studies. . BMC Med Res Methodol14, 43.
23.
WangR, HuangC, WuQ, LiuL, GuanL, XuT (2021) Evaluation of the quality of animal experiment report electroacupuncture intervention for neurogenic bladder after spinal cord injury based on SYRCLE risk assessment tool and experimental research report specification. . Chin J Comp Med31, 76–87.
24.
WangL, PangR, LiuJ, ZhangA (2021) Effect of targeting mitochondria on spinal cord injury: A systematic review based on animal experiments. . Chin J Rehabil Theory Pract27, 574–582.
25.
KilkennyC, ParsonsN, KadyszewskiE, FestingMF, CuthillIC, FryD, HuttonJ, AltmanDG (2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One4, e7824.
ZhangY, CaoS, SunP, HeH, YangC, ChenX, ShenC, WangX, ChenZ, BergD, DuanS, LiX (2016) Loss of MeCP2 in cholinergic neurons causes part of RTT-like phenotypes via α7 receptor in hippocampus. . Cell Res26, 728–742.
28.
LagakosSW (2006) The challenge of subgroup analyses–reporting without distorting. . N Engl J Med354, 1667–1669.
29.
Neha, SodhiRK, JaggiAS, SinghN (2014) Animal models of dementia and cognitive dysfunction. . Life Sci109, 73–86.
ChenZ, ZhangY (2022) Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives. . Zool Res43, 1026–1040.
33.
LiC, EbrahimiA, SchluesenerH (2013) Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer’s disease. . Ageing Res Rev12, 116–140.
34.
GoateA, Chartier-HarlinMC, MullanM, BrownJ, CrawfordF, FidaniL, GiuffraL, HaynesA, IrvingN, JamesL, et al.(1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. . Nature349, 704–706.
35.
Chartier-HarlinMC, CrawfordF, HouldenH, WarrenA, HughesD, FidaniL, GoateA, RossorM, RoquesP, HardyJ, et al.(1991) Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. . Nature353, 844–846.
36.
MullanM, CrawfordF, AxelmanK, HouldenH, LiliusL, WinbladB, LannfeltL (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. . Nat Genet1, 345–347.
37.
RogaevEI, SherringtonR, RogaevaEA, LevesqueG, IkedaM, LiangY, ChiH, LinC, HolmanK, TsudaT, et al.(1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. . Nature376, 775–778.
MuckeL, MasliahE, YuGQ, MalloryM, RockensteinEM, TatsunoG, HuK, KholodenkoD, Johnson-WoodK, McConlogueL (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. . J Neurosci20, 4050–4058.
40.
PozuetaJ, LefortR, RibeEM, TroyCM, ArancioO, ShelanskiM (2013) Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. . Nat Commun4, 1939.
41.
SaganichMJ, SchroederBE, GalvanV, BredesenDE, KooEH, HeinemannSF (2006) Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. . J Neurosci26, 13428–13436.
42.
SanchezPE, ZhuL, VerretL, VosselKA, OrrAG, CirritoJR, DevidzeN, HoK, YuGQ, PalopJJ, MuckeL (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A109, E2895–2903.
43.
WilkeSA, RaamT, AntoniosJK, BushongEA, KooEH, EllismanMH, GhoshA (2014) Specific disruption of hippocampal mossy fiber synapses in a mouse model of familial Alzheimer’s disease. PLoS One9, e84349.
44.
WrightAL, ZinnR, HohensinnB, KonenLM, BeynonSB, TanRP, ClarkIA, AbdipranotoA, VisselB (2013) Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One8, e59586.
45.
HongS, Beja-GlasserVF, NfonoyimBM, FrouinA, LiS, RamakrishnanS, MerryKM, ShiQ, RosenthalA, BarresBA, LemereCA, SelkoeDJ, StevensB (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. . Science352, 712–716.
46.
NaderK, SchafeGE, LeDoux JE (2000) Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. . Nature406, 722–726.
GuertinDA, StevensDM, ThoreenCC, BurdsAA, KalaanyNY, MoffatJ, BrownM, FitzgeraldKJ, SabatiniDM (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. . Dev Cell11, 859–871.
49.
SarbassovDD, AliSM, SabatiniDM (2005) Growing roles for the mTOR pathway. . Curr Opin Cell Biol17, 596–603.
50.
MizushimaN (2010) The role of the Atg1/ULK1 complex in autophagy regulation. . Curr Opin Cell Biol22, 132–139.
ZengZ, Sarbassov dosD, SamudioIJ, YeeKW, MunsellMF, Ellen JacksonC, GilesFJ, SabatiniDM, AndreeffM, KonoplevaM (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. . Blood109, 3509–3512.
53.
BjedovI, RallisC (2020) The target of rapamycin signalling pathway in ageing and lifespan regulation. . Genes (Basel)11, 1043.
54.
LiuGY, SabatiniDM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. . Nat Rev Mol Cell Biol21, 183–203.
55.
YinS, LiuL, GanW (2021) The roles of post-translational modifications on mTOR signaling. . Int J Mol Sci22, 1784.
56.
AnWL, CowburnRF, LiL, BraakH, AlafuzoffI, IqbalK, IqbalIG, WinbladB, PeiJJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. . Am J Pathol163, 591–607.
57.
TangZ, BereczkiE, ZhangH, WangS, LiC, JiX, BrancaRM, LehtiöJ, GuanZ, FilipcikP, XuS, WinbladB, PeiJJ (2013) Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: Implication for Alzheimer disease. . J Biol Chem288, 15556–15570.
58.
LaiC, ChenZ, DingY, ChenQ, SuS, LiuH, NiR, TangZ (2022) Rapamycin attenuated zinc-induced tau phosphorylation and oxidative stress in rats: Involvement of dual mTOR/p70S6K and Nrf2/HO-1 pathways. . Front Immunol13, 782434.
59.
RubinszteinDC, GestwickiJE, MurphyLO, KlionskyDJ (2007) Potential therapeutic applications of autophagy. . Nat Rev Drug Discov6, 304–312.
60.
FornaiF, Puglisi-AllegraS (2021) Autophagy status as a gateway for stress-induced catecholamine interplay in neurodegeneration. . Neurosci Biobehav Rev123, 238–256.
PangY, LinW, ZhanL, ZhangJ, ZhangS, JinH, ZhangH, WangX, LiX (2022) Inhibiting autophagy pathway of PI3K/AKT/mTOR promotes apoptosis in SK-N-SH cell model of Alzheimer’s disease. . J Healthc Eng2022, 6069682.
64.
LingD, SalvaterraPM (2009) A central role for autophagy in Alzheimer-type neurodegeneration. . Autophagy5, 738–740.
65.
LingD, SalvaterraPM (2011) Brain aging and Aβ– neurotoxicity converge via deterioration in autophagy-lysosomal system: A conditional Drosophila model linking Alzheimer’s neurodegeneration with aging. . Acta Neuropathol121, 183–191.
66.
MadeoF, EisenbergT, KroemerG (2009) Autophagy for the avoidance of neurodegeneration. . Genes Dev23, 2253–2259.
GaoY, TanL, YuJT, TanL (2018) Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies. . Curr Alzheimer Res15, 283–300.
74.
WangX, XiaW, LiK, ZhangY, GeW, MaC (2019) Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse. . J Neurol Sci399, 125–139.
75.
WangH, FuJ, XuX, YangZ, ZhangT (2021) Rapamycin activates mitophagy and alleviates cognitive and synaptic plasticity deficits in a mouse model of Alzheimer’s disease. . J Gerontol A Biol Sci Med Sci76, 1707–1713.
76.
PraticòD (2008) Oxidative stress hypothesis in Alzheimer’s disease: A reappraisal. . Trends Pharmacol Sci29, 609–615.
77.
ZhangT, XiaY, HuL, ChenD, GanCL, WangL, MeiY, LanG, ShuiX, TianY, LiR, ZhangM, LeeTH (2022) Death-associated protein kinase 1 mediates Aβ42 aggregation-induced neuronal apoptosis and tau dysregulation in Alzheimer’s disease. . Int J Biol Sci18, 693–706.
78.
LinM, WangM, ZhangM, WangC (2017) Effect of Rapamycin on the learning and memory and the expression of AB1-42 in hippocampus of APP/PS1 transgenic mice. . J Zunyi Med Univ40, 254–258.
79.
ZhangM (2014) Influence of Rapamycin on the Expression ofβ-amyloid Protein in Model Mice with Alzheimer’s disease. Zunyi Med Univ.
80.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. . Neuron39, 409–421.
81.
BillingsLM, OddoS, GreenKN, McGaughJL, LaFerlaFM (2005) Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. . Neuron45, 675–688.
SquireLR (1992) Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. . Psychol Rev99, 195–231.
84.
PaulsE, BayodS, MateoL, AlcaldeV, Juan-BlancoT, Sánchez-SotoM, SaidoTC, SaitoT, Berrenguer-LlergoA, AttoliniCS, GayM, de OliveiraE, Duran-FrigolaM, AloyP (2021) Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in App(NL-G-F), App(NL-F), and 3×Tg-AD mouse models. . Genome Med13, 168.
85.
MeredithSC (2005) Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. . Ann N Y Acad Sci1066, 181–221.
86.
SantacruzK, LewisJ, SpiresT, PaulsonJ, KotilinekL, IngelssonM, GuimaraesA, DeTureM, RamsdenM, McGowanE, ForsterC, YueM, OrneJ, JanusC, MariashA, KuskowskiM, HymanB, HuttonM, AsheKH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. . Science309, 476–481.
87.
Díaz-TroyaS, Pérez-PérezME, FlorencioFJ, CrespoJL (2008) The role of TOR in autophagy regulation from yeast to plants and mammals. . Autophagy4, 851–865.
88.
CuiX, WeiZ, ShenH, ZhangJ, DaiX, ZhangJ, ChenX, ZengY (2021) Activation of LC3-mediated autophagy by rapamycin improves cognitive function of ApoE4/5×FAD mice. . Chin J Pathophysiol37, 1400–1408.
89.
OakleyH, ColeSL, LoganS, MausE, ShaoP, CraftJ, Guillozet-BongaartsA, OhnoM, DisterhoftJ, Van EldikL, BerryR, VassarR (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. . J Neurosci26, 10129–10140.
90.
SullivanPM, MezdourH, ArataniY, KnouffC, NajibJ, ReddickRL, QuarfordtSH, MaedaN (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. . J Biol Chem272, 17972–17980.
91.
NeunerSM, HeuerSE, HuentelmanMJ, O’ConnellKMS, KaczorowskiCC (2019) Harnessing genetic complexity to enhance translatability of Alzheimer’s disease mouse models: A path toward precision medicine. Neuron101, 399–411.e395.
92.
RodriguezGA, TaiLM, LaDuMJ, RebeckGW (2014) Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. . J Neuroinflammation11, 111.
93.
BellRD, WinklerEA, SinghI, SagareAP, DeaneR, WuZ, HoltzmanDM, BetsholtzC, ArmulikA, SallstromJ, BerkBC, ZlokovicBV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. . Nature485, 512–516.
94.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. . Science298, 789–791.
95.
JiaK, ChenD, RiddleDL (2004) The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. . Development131, 3897–3906.
96.
VellaiT, Takacs-VellaiK, ZhangY, KovacsAL, OroszL, MüllerF (2003) Genetics: Influence of TOR kinase on lifespan in C. elegans. . Nature426, 620.
97.
RöskamS, NeffF, SchwartingR, BacherM, DodelR (2010) APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. . Neurosci Biobehav Rev34, 487–499.
98.
BallatoreC, LeeVM, TrojanowskiJQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. . Nat Rev Neurosci8, 663–672.
99.
IqbalK, LiuF, GongCX (2016) Tau and neurodegenerative disease: The story so far. . Nat Rev Neurol12, 15–27.
100.
MartinL, LatypovaX, WilsonCM, MagnaudeixA, PerrinML, YardinC, TerroF (2013) Tau protein kinases: Involvement in Alzheimer’s disease. . Ageing Res Rev12, 289–309.
101.
BiecheleG, FranzmeierN, BlumeT, EwersM, LuqueJM, EckenweberF, SacherC, BeyerL, Ruch-RubinsteinF, LindnerS, GildehausFJ, von Ungern-SternbergB, CummingP, BartensteinP, RomingerA, HöglingerGU, HermsJ, BrendelM (2020) Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. . J Neuroinflammation17, 374.
102.
OddoS, BillingsL, KesslakJP, CribbsDH, LaFerlaFM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. . Neuron43, 321–332.
103.
EjazHW, WangW, LangM (2020) Copper toxicity links to pathogenesis of Alzheimer’s disease and therapeutics approaches. . Int J Mol Sci21, 7660.
104.
ReddyPH, OliverDM (2019) Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer’s disease. . Cells8, 488.
OddoS, CaccamoA, TsengB, ChengD, VasilevkoV, CribbsDH, LaFerlaFM (2008) Blocking Abeta42 accumulation delays the onset and progression of tau pathology via theCterminus of heat shock protein70-interacting protein: A mechanistic link between Abeta and tau pathology. J Neurosci28, 12163–12175
107.
GuoT, HobbsDW (2006) Development of BACE1 inhibitors for Alzheimer’s disease. . Curr Med Chem13, 1811–1829.
108.
LiF, WangY, YangH, XuY, ZhouX, ZhangX, XieZ, BiJ (2019) The effect of BACE1-AS on β-amyloid generation by regulating BACE1 mRNA expression. . BMC Mol Biol20, 23.
109.
HarrisonDE, StrongR, SharpZD, NelsonJF, AstleCM, FlurkeyK, NadonNL, WilkinsonJE, FrenkelK, CarterCS, PahorM, JavorsMA, FernandezE, MillerRA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. . Nature460, 392–395.
110.
OhJ, TamborindeguyC (2023) Treatment of rapamycin and evaluation of an autophagic response in the gut of Bactericera cockerelli (Sulč). . Insects14.
111.
TramutolaA, LanzillottaC, BaroneE, ArenaA, ZulianiI, MoscaL, BlarzinoC, ButterfieldDA, PerluigiM, Di DomenicoF (2018) Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. . Transl Neurodegener7, 28.
112.
QuerfurthH, LeeHK (2021) Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. . Mol Neurodegener16, 44.
113.
OddoS (2012) The role of mTOR signaling in Alzheimer disease. . Front Biosci (Schol Ed)4, 941–952.
PerluigiM, DiDomenico F, BaroneE, ButterfieldDA (2021) mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder. . Free Radic Biol Med169, 382–396.
116.
CaccamoA, MagriA, MedinaDX, WiselyEV, Lopez-ArandaMF, SilvaAJ, OddoS (2013) mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer’s disease and other tauopathies. . Aging Cell12, 370–380.
117.
YanZ, FuB, HeD, ZhangY, LiuJ, ZhangX (2018) The relationship between oxidized low-density lipoprotein and related ratio and acute cerebral infarction. Medicine (Baltimore)97, e12642.
118.
DennisBA, ErgulA, GowerBA, AllisonJD, DavisCL (2013) Oxidative stress and cardiovascular risk in overweight children in an exercise intervention program. . Child Obes9, 15–21.
119.
LiX, XieH, ZhanR, ChenD (2018) Effect of double bond position on 2-phenyl-benzofuran antioxidants: A comparative study of Moracin C and Iso-Moracin C. . Molecules23.
120.
DamianoS, MuscarielloE, La RosaG, Di MaroM, MondolaP, SantilloM (2019) Dual role of reactive oxygen species in muscle function: Can antioxidant dietary supplements counteract age-related sarcopenia? . Int J Mol Sci20, 3815.
121.
WangL, YinYL, LiuXZ, ShenP, ZhengYG, LanXR, LuCB, WangJZ (2020) Current understanding of metal ions in the pathogenesis of Alzheimer’s disease. . Transl Neurodegener9, 10.
WangX, SuB, LeeHG, LiX, PerryG, SmithMA, ZhuX (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. . J Neurosci29, 9090–9103.
128.
FardghassemiY, TauffenbergerA, GosselinS, ParkerJA (2017) Rescue of ATXN3 neuronal toxicity in Caenorhabditiselegans by chemical modification of endoplasmic reticulum stress. . Dis Model Mech10, 1465–1480.
129.
WangMJ, HuangHY, ChenWF, ChangHF, KuoJS (2010) Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. . J Neuroinflammation7, 99.
130.
García-EscuderoV, Martín-MaestroP, PerryG, AvilaJ (2013) Deconstructing mitochondrial dysfunction in Alzheimer disease. . Oxid Med Cell Longev2013, 162152.
131.
DavidDC, HauptmannS, ScherpingI, SchuesselK, KeilU, RizzuP, RavidR, DröseS, BrandtU, MüllerWE, EckertA, GötzJ (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. . J Biol Chem280, 23802–23814.
132.
ChengY, BaiF (2018) The association of tau with mitochondrial dysfunction in Alzheimer’s disease. . Front Neurosci12, 163.
133.
MajdS, PowerJHT (2018) Oxidative stress and decreased mitochondrial superoxide dismutase 2 and peroxiredoxins 1 and 4 based mechanism of concurrent activation of AMPK and mTOR in Alzheimer’s disease. . Curr Alzheimer Res15, 764–776.
134.
MecocciP, BoccardiV, CecchettiR, BastianiP, ScamosciM, RuggieroC, BaroniM (2018) A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. . J Alzheimers Dis62, 1319–1335.
135.
RichterC (1995) Oxidative damage to mitochondrial DNA and its relationship to ageing. . Int J Biochem Cell Biol27, 647–653.
136.
DonatiA, TaddeiM, CavalliniG, BergaminiE (2006) Stimulation of macroautophagy can rescue older cells from 8-OHdG mtDNA accumulation: A safe and easy way to meet goals in the SENS agenda. . Rejuvenation Res9, 408–412.
137.
HerreroA, BarjaG (1999) 8-oxo-deoxyguanosine levels in heart and brain mitochondrial and nuclear DNA of two mammals and three birds in relation to their different rates of aging. . Aging (Milano)11, 294–300.
HauptmannS, ScherpingI, DröseS, BrandtU, SchulzKL, JendrachM, LeunerK, EckertA, MüllerWE (2009) Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. . Neurobiol Aging30, 1574–1586.
146.
MoreiraPI, CarvalhoC, ZhuX, SmithMA, PerryG (2010) Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. . Biochim Biophys Acta1802, 2–10.
WoodWG, LiL, MüllerWE, EckertGP (2014) Cholesterol as a causative factor in Alzheimer’s disease: A debatable hypothesis. . J Neurochem129, 559–572.
152.
SegattoM, LeboffeL, TrapaniL, PallottiniV (2014) Cholesterol homeostasis failure in the brain: Implications for synaptic dysfunction and cognitive decline. Curr Med Chem21, 2788–2802
153.
JohansonCE, StopaEG, McMillanPN (2011) The blood-cerebrospinal fluid barrier: Structure and functional significance. . Methods Mol Biol686, 101–131.
154.
MarwarhaG, GhribiO (2015) Does the oxysterol 27-hydroxycholesterol underlie Alzheimer’s disease-Parkinson’s disease overlap? . Exp Gerontol68, 13–18.
155.
CraftS, PeskindE, SchwartzMW, SchellenbergGD, RaskindM, PorteDJr., (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: Relationship to severity of dementia and apolipoprotein E genotype. . Neurology50, 164–168.
DiasIH, PolidoriMC, GriffithsHR (2014) Hyper-cholesterolaemia-induced oxidative stress at the blood-brain barrier. . Biochem Soc Trans42, 1001–1005.
158.
PetrovAM, KasimovMR, ZefirovAL (2017) Cholesterol in the pathogenesis of Alzheimer’s, Parkinson’s diseases and autism: Link to synaptic dysfunction. . Acta Naturae9, 26–37.
159.
HussainG, WangJ, RasulA, AnwarH, ImranA, QasimM, ZafarS, KamranSKS, RazzaqA, AzizN, AhmadW, ShabbirA, IqbalJ, BaigSM, SunT (2019) Role of cholesterol and sphingolipids in brain development and neurological diseases. . Lipids Health Dis18, 26.
160.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. . Science261, 921–923.
ZhangH, ShaoL, LinZ, LongQX, YuanH, CaiL, JiangG, GuoX, YangR, ZhangZ, ZhangB, LiuF, LiZ, MaQ, ZhangYW, HuangAL, WangZ, ZhaoY, XuH (2022) APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. . Signal Transduct Target Ther7, 261.
163.
FeringaFM, vander Kant R (2021) Cholesterol and Alzheimer’s disease; from risk genes to pathological effects. . Front Aging Neurosci13, 690372.
164.
IshiiM, IadecolaC (2020) Risk factor for Alzheimer’s disease breaks the blood-brain barrier. . Nature581, 31–32.
165.
MalikB, FernandesC, KillickR, WroeR, UsardiA, WilliamsonR, KellieS, AndertonBH, ReynoldsCH (2012) Oligomeric amyloid-β peptide affects the expression of genes involved in steroid and lipid metabolism in primary neurons. . Neurochem Int61, 321–333.
166.
DietschyJM, TurleySD (2004) Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. . J Lipid Res45, 1375–1397.
167.
ChenZ, YuanZ, YangS, ZhuY, XueM, ZhangJ, LengL (2023) Brain energy metabolism: Astrocytes in neurodegenerative diseases. . CNS Neurosci Ther29, 24–36.
168.
ChenY, QinC, HuangJ, TangX, LiuC, HuangK, XuJ, GuoG, TongA, ZhouL (2020) The role of astrocytes in oxidative stress of central nervous system: A mixed blessing. Cell Prolif53, e12781.
169.
MächlerP, WyssMT, ElsayedM, StobartJ, GutierrezR, von Faber-CastellA, KaelinV, ZuendM, San MartínA, Romero-GómezI, Baeza-LehnertF, LengacherS, SchneiderBL, AebischerP, MagistrettiPJ, BarrosLF, WeberB (2016) In vivo evidence for a lte gradient from astrocytes to neurons. . Cell Metab23, 94–102.
170.
ZhangS, LachanceBB, MattsonMP, JiaX (2021) Glucose metabolic crosstalk and regulation in brain function and diseases. . Prog Neurobiol204, 102089.
171.
StaurenghiE, GiannelliS, TestaG, SotteroB, LeonarduzziG, GambaP (2021) Cholesterol dysmetabolism in Alzheimer’s disease: A starring role for astrocytes? . Antioxidants (Basel)10, 1890.
172.
CloughesyTF, YoshimotoK, NghiemphuP, BrownK, DangJ, ZhuS, HsuehT, ChenY, WangW, YoungkinD, LiauL, MartinN, BeckerD, BergsneiderM, LaiA, GreenR, OglesbyT, KoletoM, TrentJ, HorvathS, MischelPS, MellinghoffIK, SawyersCL (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med5, e8.
173.
Iturria-MedinaY, SoteroRC, ToussaintPJ, Mateos-PérezJM, EvansAC (2016) Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. . Nat Commun7, 11934.
MattssonN, TosunD, InselPS, SimonsonA, JackCRJr., BeckettLA, DonohueM, JagustW, SchuffN, WeinerMW (2014) Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment. . Brain137, 1550–1561.
178.
NiwaK, CarlsonGA, IadecolaC (2000) Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. . J Cereb Blood Flow Metab20, 1659–1668.
179.
MaierFC, WehrlHF, SchmidAM, MannheimJG, WiehrS, LerdkraiC, CalaminusC, StahlschmidtA, YeL, BurnetM, StillerD, SabriO, ReischlG, StaufenbielM, GaraschukO, JuckerM, PichlerBJ (2014) Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. . Nat Med20, 1485–1492.
180.
BinnewijzendMA, BenedictusMR, KuijerJP, van der FlierWM, TeunissenCE, PrinsND, WattjesMP, van BerckelBN, ScheltensP, BarkhofF (2016) Cerebral perfusion in the predementia stages of Alzheimer’s disease. . Eur Radiol26, 506–514.
181.
StomrudE, ForsbergA, HägerströmD, RydingE, BlennowK, ZetterbergH, MinthonL, HanssonO, LondosE (2012) CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. . Dement Geriatr Cogn Disord33, 156–163.
182.
KimbroughIF, RobelS, RobersonED, SontheimerH (2015) Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer’s disease. . Brain138, 3716–3733.
183.
TongXK, HamelE (1999) Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer’s disease. . Neuroscience92, 163–175.
184.
ZenaroE, PiacentinoG, ConstantinG (2017) The blood-brain barrier in Alzheimer’s disease. . Neurobiol Dis107, 41–56.
JeynesB, ProviasJ (2009) Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. . Neurosci Lett463, 244–248.
188.
TarantiniS, TranCHT, GordonGR, UngvariZ, CsiszarA (2017) Impaired neurovascular coupling in aging and Alzheimer’s disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. . Exp Gerontol94, 52–58.
189.
Van SkikeCE, JahrlingJB, OlsonAB, SayreNL, HussongSA, UngvariZ, LechleiterJD, GalvanV (2018) Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol314, H693–h703.
Van SkikeCE, HussongSA, HernandezSF, BanhAQ, DeRosaN, GalvanV (2021) mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer’s disease. . J Neurosci41, 4305–4320.
192.
MorrisJK, BurnsJM (2012) Insulin: An emerging treatment for Alzheimer’s disease dementia?Curr Neurol Neurosci Rep12, 520–527 .
193.
SteenE, TerryBM, RiveraEJ, CannonJL, NeelyTR, TavaresR, XuXJ, WandsJR, dela Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? . J Alzheimers Dis7, 63–80.
ChornenkyyY, WangWX, WeiA, NelsonPT (2019) Alzheimer’s disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. . Brain Pathol29, 3–17.
201.
SonSM, SongH, ByunJ, ParkKS, JangHC, ParkYJ, Mook-JungI (2012) Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. . Diabetes61, 3126–3138.
202.
SonSM, SongH, ByunJ, ParkKS, JangHC, ParkYJ, Mook-JungI (2012) Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. . Autophagy8, 1842–1844.
203.
OzcelikS, FraserG, CastetsP, SchaefferV, SkachokovaZ, BreuK, ClavagueraF, SinnreichM, KapposL, GoedertM, TolnayM, WinklerDT (2013) Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One8, e62459.
204.
OrrME, SalinasA, BuffensteinR, OddoS (2014) Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer’s disease pathology. . Neurobiol Aging35, 1233–1242.
205.
PaschoalVA, AmanoMT, BelchiorT, MagdalonJ, ChiminP, AndradeML, Ortiz-SilvaM, CastroÉ, YamashitaAS, Rosa NetoJC, CâmaraNO, FestucciaWT (2017) mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function. . Immunobiology222, 261–271.
206.
BitelCL, KasinathanC, KaswalaRH, KleinWL, FrederiksePH (2012) Amyloid-β and tau pathology of Alzheimer’s disease induced by diabetes in a rabbit animal model. . J Alzheimers Dis32, 291–305.
207.
ChenJ, LongZ, LiY, LuoM, LuoS, HeG (2019) Alteration of the Wnt/GSK3β/β-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer’s disease model. . Int J Mol Med44, 313–323.
208.
AltarejosJY, MontminyM (2011) CREB and the CRTC co-activators: Sensors for hormonal and metabolic signals. . Nat Rev Mol Cell Biol12, 141–151.
MillerRA, HarrisonDE, AstleCM, BaurJA, BoydAR, de CaboR, FernandezE, FlurkeyK, JavorsMA, NelsonJF, OrihuelaCJ, PletcherS, SharpZD, SinclairD, StarnesJW, WilkinsonJE, NadonNL, StrongR (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. . J Gerontol A Biol Sci Med Sci66, 191–201.
211.
KaeberleinM, GalvanV (2019) Rapamycin and Alzheimer’s disease: Time for a clinical trial?Sci Transl Med11, eaar4289.
212.
SankhalaK, MitaA, KellyK, MahalingamD, GilesF, MitaM (2009) The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. . Target Oncol4, 135–142.
213.
PratleyRE, KanapkaLG, RickelsMR, AhmannA, AleppoG, BeckR, BhargavaA, BodeBW, CarlsonA, ChaytorNS, FoxDS, GolandR, HirschIB, KrugerD, KudvaYC, LevyC, McGillJB, PetersA, PhilipsonL, Philis-TsimikasA, Pop-BusuiR, ShahVN, ThompsonM, VendrameF, VerdejoA, WeinstockRS, YoungL, MillerKM (2020) Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial. . JAMA323, 2397–2406.
214.
KraigE, LinehanLA, LiangH, RomoTQ, LiuQ, WuY, BenavidesAD, CurielTJ, JavorsMA, MusiN, ChiodoL, KoekW, GelfondJAL, KelloggDLJr.
(2018) A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. . Exp Gerontol105, 53–69.
215.
SchulzKF, ChalmersI, HayesRJ, AltmanDG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. . JAMA273, 408–412.
216.
ZhanL, MaX, HanX, CuiA, WangZ, HuangY (2017) Effects of rapamycin on levels of blood glucose and lipids in Alzheimer’s disease mouse model. . J Trop Med17, 1580–1582.
XieY, WangK, NiuM (2020) Effects of sevoflurane preconditioning on cognitive dysfunction in aged rats and the role of autophagy in the hippocampus. . Chin J Comp Med30, 84–90.
